RU2546521C2 - Лекарственные формы для перорального применения, содержащие ацетат ликарбазепина - Google Patents

Лекарственные формы для перорального применения, содержащие ацетат ликарбазепина Download PDF

Info

Publication number
RU2546521C2
RU2546521C2 RU2010121135/15A RU2010121135A RU2546521C2 RU 2546521 C2 RU2546521 C2 RU 2546521C2 RU 2010121135/15 A RU2010121135/15 A RU 2010121135/15A RU 2010121135 A RU2010121135 A RU 2010121135A RU 2546521 C2 RU2546521 C2 RU 2546521C2
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
granules
composition according
bulk density
acetate
Prior art date
Application number
RU2010121135/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010121135A (ru
Inventor
Теофилу Кардозу Ди ВАШКУНСЕЛУШ
ЛИМА Рикарду Жоржи Дуж САНТУШ
КОШТА Руй Сердейра Ди КАМПУШ
Original Assignee
БИАЛ-ПОРТЕЛА энд КА., С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2546521(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by БИАЛ-ПОРТЕЛА энд КА., С.А. filed Critical БИАЛ-ПОРТЕЛА энд КА., С.А.
Publication of RU2010121135A publication Critical patent/RU2010121135A/ru
Application granted granted Critical
Publication of RU2546521C2 publication Critical patent/RU2546521C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2010121135/15A 2007-10-26 2008-10-24 Лекарственные формы для перорального применения, содержащие ацетат ликарбазепина RU2546521C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98279007P 2007-10-26 2007-10-26
US60/982,790 2007-10-26
PCT/PT2008/000043 WO2009054743A1 (en) 2007-10-26 2008-10-24 Oral dosage forms comprising licarbazξpine acetate

Publications (2)

Publication Number Publication Date
RU2010121135A RU2010121135A (ru) 2011-12-10
RU2546521C2 true RU2546521C2 (ru) 2015-04-10

Family

ID=40254311

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010121135/15A RU2546521C2 (ru) 2007-10-26 2008-10-24 Лекарственные формы для перорального применения, содержащие ацетат ликарбазепина

Country Status (24)

Country Link
US (5) US8372431B2 (en:Method)
EP (2) EP2214636B1 (en:Method)
JP (4) JP2011500797A (en:Method)
KR (3) KR102116087B1 (en:Method)
CN (1) CN101848698A (en:Method)
AR (1) AR069031A1 (en:Method)
AU (1) AU2008317584B2 (en:Method)
BR (1) BRPI0818680B1 (en:Method)
CA (1) CA2703313C (en:Method)
CY (1) CY1118350T1 (en:Method)
DK (1) DK2214636T3 (en:Method)
ES (2) ES2898202T3 (en:Method)
HR (1) HRP20161329T1 (en:Method)
HU (1) HUE030788T2 (en:Method)
IL (1) IL205160A0 (en:Method)
LT (1) LT2214636T (en:Method)
MX (1) MX2010004323A (en:Method)
PL (1) PL2214636T3 (en:Method)
PT (2) PT3202392T (en:Method)
RS (1) RS55376B1 (en:Method)
RU (1) RU2546521C2 (en:Method)
SI (1) SI2214636T1 (en:Method)
UA (1) UA110012C2 (en:Method)
WO (1) WO2009054743A1 (en:Method)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018004391A1 (ru) * 2016-06-29 2018-01-04 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
EA037195B1 (ru) * 2018-03-28 2021-02-18 Акционерное Общество "Химфарм" Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
CA2768656C (en) 2009-07-21 2016-10-04 Keryx Biopharmaceuticals, Inc. Ferric citrate dosage forms
CA2769181C (en) 2009-07-27 2017-11-28 Bial-Portela & Ca., S.A. Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia
ES2898348T3 (es) 2009-10-26 2022-03-07 Merck Sharp & Dohme Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa
US20120121703A1 (en) * 2010-07-20 2012-05-17 Japan Tobacco Inc. Tablet containing ferric citrate
TR201008460A1 (tr) * 2010-10-15 2012-05-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Eslikarbazepinin saşe formülasyonları.
MX350531B (es) 2010-12-31 2017-09-08 BIAL PORTELA & Cª S A Granulados que comprenden acetato de eslicarbazepina.
CA2847235C (en) 2011-08-26 2020-07-07 Bial - Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
EP3103444A1 (en) 2015-06-09 2016-12-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of lacosamide and eslicarbazepine
PT3402488T (pt) 2015-12-18 2022-01-25 Jubilant Generics Ltd Formas de dosagem orais sólidas de eslicarbazepina
CN106913550B (zh) * 2017-03-10 2019-12-17 扬子江药业集团北京海燕药业有限公司 一种醋酸艾司利卡西平片的制备方法
WO2019058354A1 (en) * 2017-09-25 2019-03-28 Jubilant Generics Limited SUSPENSION OF ESLICARBAZÉPINE
US11318145B2 (en) 2018-09-25 2022-05-03 Jubilant Generics Limited Eslicarbazepine suspension
EP3851521A4 (en) 2018-09-14 2022-06-29 Keio University Method for producing astrocytes
HUP1900153A1 (hu) 2019-05-14 2020-11-30 Meditop Gyogyszeripari Kft Eszlikarbazepin-acetát tartalmú granulátum, ennek elõállítása, ezt tartalmazó egyéb gyógyszerkészítmények, és ezek alkalmazása
WO2021226256A1 (en) * 2020-05-05 2021-11-11 Neurobo Pharmaceuticals, Inc. Niclosamide formulations and methods of use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
BR9813808A (pt) * 1997-12-19 2002-05-28 Smithkline Beecham Corp Processo para produção de comprimidos para dispersão na mordida
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
IN190699B (en:Method) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
GB0111566D0 (en) 2001-05-11 2001-07-04 Portela & Ca Sa Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide
GB0112812D0 (en) 2001-05-25 2001-07-18 Portela & Ca Sa Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom
AU2003231919A1 (en) * 2002-03-14 2003-09-22 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
AU2003240654A1 (en) 2002-05-31 2003-12-19 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
DE10224170A1 (de) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
DE10230027A1 (de) 2002-07-04 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen
GB0221956D0 (en) 2002-09-20 2002-10-30 Novartis Ag Organic compounds
JP2006509735A (ja) 2002-10-17 2006-03-23 ノバルティス アクチエンゲゼルシャフト オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
US20040087642A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
GB2401605A (en) 2003-05-12 2004-11-17 Portela & Ca Sa Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US7956140B2 (en) 2004-03-17 2011-06-07 Dsm Ip Assets B.V. Polymerization catalyst comprising amidine ligand
PE20060124A1 (es) 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
AR048318A1 (es) 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
GB2416167A (en) 2004-07-13 2006-01-18 Portela & Ca Sa Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides
EP1787642A1 (en) 2004-11-10 2007-05-23 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
GB0425320D0 (en) 2004-11-17 2004-12-22 Johnson Matthey Plc Diamines
GB2422149A (en) 2005-01-14 2006-07-19 Portela & Ca Sa Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0520258A2 (pt) 2005-05-06 2009-09-15 Portela & Ca Sa uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
CN101217959A (zh) 2005-05-06 2008-07-09 坡特拉有限公司 醋酸艾司利卡西平及其应用方法
US8059672B2 (en) 2005-05-18 2011-11-15 Sprint Communications Company L.P. Internet communications between wireless base stations and service nodes
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
WO2007008576A2 (en) 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
GB0515690D0 (en) 2005-07-29 2005-09-07 Portela & Ca Sa Asymmetric catalytic reduction
WO2007029093A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
WO2007089247A1 (en) 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2029118A2 (en) 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
GB0603008D0 (en) 2006-02-14 2006-03-29 Portela & Ca Sa Method
GB2437078A (en) 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
EP2077822B1 (en) 2006-09-27 2018-04-25 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
US20080138403A1 (en) 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
PT3402488T (pt) 2015-12-18 2022-01-25 Jubilant Generics Ltd Formas de dosagem orais sólidas de eslicarbazepina

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018004391A1 (ru) * 2016-06-29 2018-01-04 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
EA037195B1 (ru) * 2018-03-28 2021-02-18 Акционерное Общество "Химфарм" Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты)

Also Published As

Publication number Publication date
US20130150348A1 (en) 2013-06-13
US8372431B2 (en) 2013-02-12
ES2607002T3 (es) 2017-03-28
PL2214636T3 (pl) 2017-02-28
RS55376B1 (sr) 2017-03-31
JP2014237658A (ja) 2014-12-18
CA2703313C (en) 2017-03-07
SI2214636T1 (sl) 2017-01-31
JP2018172407A (ja) 2018-11-08
JP2017014233A (ja) 2017-01-19
AR069031A1 (es) 2009-12-23
BRPI0818680A2 (pt) 2017-05-02
EP3202392B1 (en) 2021-08-25
DK2214636T3 (en) 2017-01-16
HUE030788T2 (en) 2017-06-28
AU2008317584B2 (en) 2015-01-22
PT2214636T (pt) 2016-12-20
WO2009054743A1 (en) 2009-04-30
US20170112850A1 (en) 2017-04-27
US20090110722A1 (en) 2009-04-30
US10912781B2 (en) 2021-02-09
CA2703313A1 (en) 2009-04-30
KR20170004034A (ko) 2017-01-10
HRP20161329T1 (hr) 2016-12-02
IL205160A0 (en) 2010-11-30
KR102116087B1 (ko) 2020-05-28
AU2008317584A1 (en) 2009-04-30
MX2010004323A (es) 2010-05-05
JP2011500797A (ja) 2011-01-06
KR20190000929A (ko) 2019-01-03
LT2214636T (lt) 2016-11-25
EP2214636B1 (en) 2016-09-28
US9566244B2 (en) 2017-02-14
US20210322436A1 (en) 2021-10-21
UA110012C2 (uk) 2015-11-10
PT3202392T (pt) 2021-11-23
CN101848698A (zh) 2010-09-29
CY1118350T1 (el) 2017-06-28
EP2214636A1 (en) 2010-08-11
BRPI0818680B1 (pt) 2022-05-24
KR20100093057A (ko) 2010-08-24
EP3202392A1 (en) 2017-08-09
RU2010121135A (ru) 2011-12-10
US20140343043A1 (en) 2014-11-20
JP6043758B2 (ja) 2016-12-14
ES2898202T3 (es) 2022-03-04

Similar Documents

Publication Publication Date Title
US10912781B2 (en) Pharmaceutical composition comprising licarbazepine acetate
KR101468738B1 (ko) 경구 용량 형태
US20110014282A1 (en) Pharmaceutical composition for poorly soluble drugs
EP2635263B1 (en) A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium